E. Van Braeckel (Ghent, Belgium), I. Ojanguren Arranz (Barcelona, Spain)
Introduction
E. Van Braeckel (Ghent, Belgium), I. Ojanguren Arranz (Barcelona, Spain)
|  |
Airway remodeling in COVID-19 lungs
V. Geudens (Leuven, Belgium), J. Van Slambrouck (Leuven, Belgium), G. Aerts (Leuven, Belgium), L. Willems (Leuven, Belgium), T. Goos (Leuven, Belgium), J. Kaes (Leuven, Belgium), I. Gyselinck (Leuven, Belgium), C. Aelbrecht (Leuven, Belgium), A. Vermaut (Leuven, Belgium), H. Beeckmans (Leuven, Belgium), M. Vermant (Leuven, Belgium), C. De Fays (Leuven, Belgium), A. Sacreas (Leuven, Belgium), L. Aversa (Leuven, Belgium), K. Verstraete (Leuven, Belgium), M. Orlitová (Leuven, Belgium), A. Vanstapel (Leuven, Belgium), J. E. Mcdonough (Leuven, Belgium), C. Pilette (Leuven, Belgium), W. Janssens (Leuven, Belgium), W. A. Wuyts (Leuven, Belgium), G. M. Verleden (Leuven, Belgium), D. E. Van Raemdonck (Leuven, Belgium), R. Vos (Leuven, Belgium), G. Gayan-Ramirez (Leuven, Belgium), L. J. Ceulemans (Leuven, Belgium), B. M. Vanaudenaerde (Leuven, Belgium)
|    |
Airway microbiota profiles associated with total lung capacity after severe COVID-19
S. Stadler (Lausanne, Switzerland), E. Bernasconi (Lausanne, Switzerland), N. Ubags (Lausanne, Switzerland), L. Mercier (Lausanne, Switzerland), B. Erkosar (Lausanne, Switzerland), M. Funke-Chambour (Bern, Switzerland), C. Von Garnier (Lausanne, Switzerland)
| |
Vitamin D to prevent COVID-19 or other acute respiratory infections: phase 3 randomised controlled trial (CORONAVIT)
D. Jolliffe (London, United Kingdom), H. Holt (London, United Kingdom), M. Talaei (London, United Kingdom), A. Sheikh (Edinburgh, United Kingdom), C. Griffiths (London, United Kingdom), S. Shaheen (London, United Kingdom), C. Relton (London, United Kingdom), A. Martineau (London, United Kingdom)
| |
Faster clinical recovery with ensovibep compared to placebo in patients with mild-to-moderate COVID-19: interim results from the EMPATHY Phase 2 trial
R. Chandra (East Hanover, United States), L. Abrishamian (Torrance, United States), M. Bonten (Utrecht, Netherlands), P. Fustier (Zurich-Schlieren, Switzerland), K. Gedif (Fort Worth, Tx, United States), S. Goncalves (Basel, Switzerland), A. Igbinadolor (Monroe, United States), J. Kingsley (Columbus, United States), C. Knutson (Cambridge, United States), N. Kumarasamy (Chennai, India), P. Legenne (Zurich-Schlieren, Switzerland), M. Mekebeb-Reuter (George, South Africa), K. Ramanathan (Basel, Switzerland), E. Reshetnyak (East Hanover, United States), J. Rosa (Gauteng, South Africa), M. Soergel (Zurich-Schlieren, Switzerland), D. Solai Elango (Hyderabad, India), V. Stavropoulou (Zurich-Schlieren, Switzerland), N. Stojcheva (Zurich-Schlieren, Switzerland), M. Stumpp (Zurich-Schlieren, Switzerland), A. Tietz (Basel, Switzerland)
| |
Major candidate variables to guide personalized treatment with corticosteroids in critically ill patients with COVID-19: CIBERESUCICOVID study
A. Motos Galera (Barcelona, Spain), C. Cillóniz (Barcelona, Spain), A. Ceccato (Barcelona, Spain), L. Fernández-Barat (Barcelona, Spain), A. Torres (Barcelona, Spain)
| |
Longitudinal profiling of the peripheral blood transcriptome identifies risk of Major Cardiac Events after Hospitalization for COVID-19
C. Hughes (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), H. Leyah (Dundee, United Kingdom), R. Hull (Sheffield, United Kingdom), A. Gilmour (Dundee, United Kingdom), D. Cassidy (Dundee, United Kingdom), H. Richardson (Dundee, United Kingdom), A. Shoemark (Dundee, United Kingdom), F. Khan (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
THE IMPACT OF BIOLOGICAL AGEING ON CLINICAL SEVERITY IN HOSPITALIZED COVID-19 PATIENTS.
E. De Waele (Sint-Niklaas, Belgium), D. Martens (Hasselt, Belgium), S. Vos (Hasselt, Belgium), E. Bijnens (Hasselt , Belgium), G. Mistiaen (Sint-Niklaas, Belgium), G. Dewyspelaere (Sint-Niklaas, Belgium), T. Nawrot (Hasselt, Belgium), P. Goeminne (Sint-Niklaas, Belgium)
| |
Characteristics and risk factors for persistent breathlessness after hospitalisation for COVID-19
L. Daines (Edinburgh (Edinburgh), United Kingdom), B. Zheng (Edinburgh (Edinburgh), United Kingdom), O. Elneima (Leicester, United Kingdom), J. Hurst (London, United Kingdom), J. Brown (London, United Kingdom), E. Sapey (Birmingham, United Kingdom), J. Chalmers (Dundee, United Kingdom), J. Quint (London, United Kingdom), P. Pfeffer (London, United Kingdom), S. Siddiqui (Leicester, United Kingdom), S. Walker (London, United Kingdom), K. Poinasamy (London, United Kingdom), L. Wain (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom), R. Evans (Leicester, United Kingdom), L. Heaney (Belfast, United Kingdom), A. De Soyza (Newcastle, United Kingdom), A. Sheikh (Edinburgh (Edinburgh), United Kingdom)
| |
The role of surfactant lipid composition in the aftermath of covid-19 infection among patients treated in intensive care
A. Holm (Gothenburg, Sweden), S. Kjellberg (Gothenburg, Sweden), B. Nellgård (Gothenburg, Sweden), K. Dalla (Gothenburg, Sweden), P. Larsson (Gothenburg, Sweden), A. Olin (Gothenburg, Sweden)
| |
Late Breaking Abstract - Real-world effectiveness of sotrovimab for the early treatment of COVID-19 in the US
C. Reyes (San Francisco, United States), M. Cheng (San Francisco, United States), D. Gibbons (Brentford, United Kingdom), H. Birch (Brentford, United Kingdom), V. Patel (Brentford, United Kingdom), C. Bell (Research Triangle Park, United States), M. Drysdale (Brentford, United Kingdom), S. Satram (San Francisco, United States)
| |